Southern Saskatchewan Ticagrelor Registry experience
Patient Preference and Adherence2014Vol. 8, pp. 1427–1427
Citations Over TimeTop 19% of 2014 papers
Payam Dehghani, Varun Chopra, Ali Bell, Lori Zulyniak, Jeff Booker, Rodney Zimmermann, William Semchuk, Andrea Lavoie, Asim N. Cheema, Sheila Kelly
Abstract
In this real-world registry of patients started on ticagrelor, a third have off-label indications and a fifth prematurely stop the medication. Premature discontinuation was an independent predictor of major life-threatening bleeding and increased composite event rate of death from vascular causes, myocardial infarction, or stroke.
Related Papers
- → Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland(2013)10 cited
- → Effect of discontinuation of ticagrelor and switching-over to other P2Y12 agents in patients with acute coronary syndrome: a single-center real-world experience from India(2021)5 cited
- → OUTCOMES IN PATIENTS TREATED WITH TICAGRELOR OR CLOPIDOGREL AFTER ACUTE CORONARY SYNDROME: EXPERIENCES FROM SWEDEHEART REGISTRY(2016)1 cited
- [The use of ticagrelor in acute coronary syndromes].(2013)
- → GAPS IN PRESCRIBING TICAGRELOR OVER CLOPIDOGREL FOR PATIENTS WITH ACUTE CORONARY SYNDROME AT TWO ACADEMIC HOSPITALS(2017)